News Brief
Summary
Pfizer has filed a second lawsuit against Novo Nordisk and Metsera, alleging anticompetitive behavior in the bidding war to acquire the obesity biotech company Metsera. Pfizer claims Novo Nordisk’s bid aims to eliminate a potential competitor. Both Novo Nordisk and Metsera have dismissed Pfizer’s claims as baseless.
Key Points
- Pfizer alleges Novo Nordisk’s acquisition of Metsera is anticompetitive and would help maintain its dominant market position.
- Novo Nordisk called Pfizer’s claims “false and without merit,” stating its offer complies with laws and benefits patients and shareholders.
- Metsera stated Pfizer is trying to litigate its way to a lower purchase price and will address the “nonsense” arguments in court.
- The lawsuit escalates a standoff over Metsera, whose pipeline could produce new competitors in the weight-loss drug market.
- Pfizer initially agreed to acquire Metsera for up to $7.3 billion, but Novo Nordisk made a rival bid valuing Metsera at around $6 billion.
- Pfizer’s first lawsuit, filed last Friday, sought to block Metsera from terminating their existing merger deal.
新闻简报
总结
辉瑞公司对诺和诺德和Metsera提起了第二起诉讼，指控在竞购肥胖症生物技术公司Metsera的过程中存在反竞争行为。辉瑞声称诺和诺德的出价旨在消除一个潜在的竞争对手。诺和诺德和Metsera均驳斥了辉瑞的指控，称其毫无根据。
关键点
- 辉瑞指控诺和诺德收购Metsera是反竞争行为，将有助于维持其市场主导地位。
- 诺和诺德称辉瑞的说法”错误且毫无根据”，并表示其出价符合法律，符合患者和股东的最佳利益。
- Metsera表示辉瑞正试图通过诉讼以更低价格收购Metsera，并将在法庭上回应这些”无稽之谈”。
- 此次诉讼升级了双方围绕Metsera的激烈对峙，该公司的研发管线可能为火爆的减肥药市场带来新的竞争者。
- 辉瑞最初同意以高达73亿美元的价格收购Metsera，但诺和诺德提出了约60亿美元的竞争性报价。
- 辉瑞于上周五提起的第一起诉讼，旨在阻止Metsera终止与其现有的合并协议。
Original Article Link: https://www.cnbc.com/2025/11/03/pfizer-files-second-lawsuit-against-novo-nordisk-metsera.html